When cleared by the FDA, LightTouch devices aim to revolutionize glaucoma prevention and treatment with:
- Superior IOP Measurement Technology
- Tonometry Beyond Eyecare Offices
- Glaucoma Data Value Creation
- Transforming The Treatment Paradigm
* Probe concept design for illustration purposes only. Actual FDA approved device may vary.
Discovering
The Problem
Loss of vision and blindness are the most expensive healthcare economic burden, costing $134 billion each year. Glaucoma is the #1 cause.
Glaucoma is the most common cause of irreversible vision loss, affecting 5.5 million people in the US and at least 160 million people globally (including undiagnosed).
Half of the people with glaucoma are undiagnosed; early visual loss frequently happens without awareness.
Controlling eye pressure is the only means of preventing irreversible visual loss from glaucoma. This requires tonometry, the measurement of eye pressure.
Why LightTouch Now?
Tonometer Innovation Sought by Key Opinion Leaders
Today’s tonometers have critical disadvantages and do not effectively facilitate the prevention of visual loss. The primary dilemma in choice of tonometer has been between accuracy or portability. This dilemma increases the risk for the most at-risk patients, who would benefit from more frequent and nighttime measurements.
Modernization of the Goldmann Applanation Tonometer (GAT)
For 65 years, the mechanical GAT has been the tonometer of choice for accuracy. However, it is bound to the eye doctor's office for use only by trained professionals, due to its training requirement and its awkward size and weight. LightTouch upgrades the GAT to the digital era, and democratizes GAT-based measurement for use by anyone, anywhere, anytime.
Transformation of Glaucoma Care
When commercially available, LightTouch will produce tonometry measurements that are simultaneously more accurate and more frequent, the data will facilitate the diagnosis and treatment of glaucoma, preventing visual loss for millions. In turn, this profusion of data will enable research that further improves individual patient care and pharmaceutical progress.
With our patented technology, LightTouch could potentially disrupt and revolutionize tonometry.
LightTouch aims to
Transform
The Treatment Paradigm.
Learn more about the latest investment opportunities.
Earlier screening and diagnosis prevents visual loss and blindness.
Frequent, accurate IOP monitoring yields better glaucoma outcomes.
Telemedicine & Patient Centered Medical Home lower costs and improve care.
Patients who know their eye pressure measurements become engaged to comply with their treatment.
The LightTouch Data Trove Aims To Facilitate
Individual Patient Care
Predictive Healthcare
Research
(Pharmaceuticals and Academic)
Value Proposition
Patented Technology
LightTouch technology for our forthcoming devices aim to be a portable, auto-calibrating, digital/objective tonometer featuring the measurement technology that eyecare professionals value most
Data Market Potential
The creation of high volume and high-quality glaucoma data, potentially unlocking revenue opportunities from pharma and other stakeholders
Intellectual Property
2
Patents Issued
1
Patent Pending
1
Trademark Issued
Clinically Validated & Published
ARVO Annual Meeting Abstract
Intraocular pressure estimates measured using a novel hand-held tonometer.
Pinakin Gunvant Davey; John Maggiano; Laz Peterson; Steve Maurath; Peter Joson
ARVO Annual Meeting Abstract
Early validation of a novel handheld digital tonometer.
John Maggiano; Laz Peterson; Steve Maurath; Peter Joson; Pinakin Gunvant Davey